Literature DB >> 29902302

Interpreting the Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma.

Hajime Uno1, Dae Hyun Kim2,3, Lee-Jen Wei4.   

Abstract

Entities:  

Mesh:

Year:  2018        PMID: 29902302     DOI: 10.1001/jamaoncol.2018.0881

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN: 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  1 in total

1.  Methods for Accommodating Nonproportional Hazards in Clinical Trials: Ready for the Primary Analysis?

Authors:  Boris Freidlin; Edward L Korn
Journal:  J Clin Oncol       Date:  2019-10-24       Impact factor: 44.544

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.